My guess is the volumes will surprise to the upside. More PR due on LYMPRO, which could happen any time. Too much leverage to just let time pass by both retailers and specs. Curious choice for Orphan PR timing, obviously GC planned this sequence w/guesses around FDA action dates.
This is a well known Irish folk song....the major happy theme is .."Good night, and joy be to you all"...we have waited a long time for real and good news, perhaps this is the end of the beginning. All the best.
Yes, ladies and gentlemen the Red Sox have dominated the Yankees yet again. Wait, wait...it looks like Derick Jeter's platinum wheel cahir has been stolen, he normally leaves it parked in one of the empty $2500 seats near 3rd base. No wait, it's A-Rod there with the wheelchair, he selling it for drugs behind the dug out. What ever happened to the best baseball team money could buy? The dynasty is a sad shadow of it's former self absorbed phoney as it gets self.....so friggen sad.
silver bullet....."MANF's lead indication is retinitis pigmentosa, and additional indications including Parkinson's disease, diabetes and Wolfram's syndrome are currently pursued. Further applications for MANF may include Alzheimer's disease, traumatic brain injury (TBI), myocardial infarction, antibiotic-induced ototoxicity and certain other rare orphan diseases currently under evaluation"
Bottom of the 9th, man on third, man on second...NYY & SOX tied up at 3 ...Red Sox up...the count to "big Poppi" is 3 and 2 ...he stretches and ...........BOOOOOOOOOOOOOMMMM, a walk off...
Should've used Lympro..
."The setback for Alzheimer's drug gantenerumab is especially disappointing, since there had been hopes that giving it in the final Phase III study to patients with so-called prodromal disease, or pre-dementia, would produce a better outcome.
Many scientists believe the best hope for treating Alzheimer's lies in giving drugs at this earlier stage, before patients' brains are wrecked
Huh, OK ...based on your assessment of trades by specific individuals or just in general. BTW, not questioning your judgement. We are due (IMO) and I support a moving upward message . The bigger the better and, in fact, massive is fine.
dol is your opinion based on observation, facts, linked events? ...hope you are right. Some trigger event (good or bad) is in the air.
This is an excellent observation. In fact some have made it a point in their incoming PR. A guy who starts AMGEN and has more money that the pope will not intentionaly mislead, legalities aside.
Light volume but a notable event, IMO. "May peace and joy be to you all."
Obama also added ..."this is not like drone attacks from the comfort of my bathroom"...this is viscious.
In most families the loss of a close family member obligates them to a period of low key maintainence. Give them a few days to get the dead in the ground. Then judge their openess.
This makes sense of course. If clinicians are able to dose and measure results in a data rich environment then correlations can be made. Real progress in clinics is possible. Rapid cycle time is an enormous issue.
Recall an old song line..."sure could use a little good news today".
This could be a good news day...
Under the new plan, barring significant safety issues, InVivo will submit two months of safety data to the FDA for the first subject enrolled in October, and will then open enrollment for the second subject in mid-January (about three months after the first subject was enrolled). Upon enrollment of the second subject, InVivo will submit to the FDA one month of safety data for that subject together with the previous subject’s data; concurrent enrollment for the remaining three subjects will then begin (about two months after the second subject is enrolled). There will be no additional mandatory holds between enrollment of the final three subjects. This differs from the previous plan, which required a mandatory three-month hold between sequential enrollment of each of the five subjects.